Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $55.11 | $18.58 | 196.60% | 229.63x | 16.62x | 16.84x | 45.14x | 1.09x | $41.15M | 0.85% | $108.58M | 1.23 | $4.86B | 90.71 | ||
| CORT | CORCEPT THERAPEUTICS INC | $71.20 | $19.15 | 271.78% | 154.78x | 135.98x | 9.67x | 11.98x | 1.46x | $119.79M | 1.61% | $637.99M | 6.11 | $7.54B | -1,098.80 | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $6.00 | $2.87 | 109.04% | 85.71x | 50.21x | 3.25x | 79.61x | 0.82x | $47.52M | 4.65% | $13.01M | 0.08 | $1.18B | 22.13 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $286.12 | $95.75 | 198.83% | 65.62x | 38.80x | 8.87x | 35.52x | 1.35x | $641.34M | 1.69% | $1.08B | 8.09 | $39.46B | 42.68 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $46.92 | $17.60 | 166.53% | 47.88x | 36.75x | 4.76x | 5.96x | 1.30x | $164.23M | 4.57% | $605.69M | 7.92 | $3.43B | 30.76 | ||
| KRYS | KRYSTAL BIOTECH INC | $293.21 | $97.22 | 201.60% | 37.83x | 36.26x | 20.58x | 6.77x | 1.80x | $237.38M | 2.76% | $1.28B | 43.59 | $8.15B | 38.10 | ||
| ADMA | ADMA BIOLOGICS INC | $7.60 | $10.66 | -28.68% | 11.01x | 7.66x | 3.52x | 4.51x | 0.37x | $107.90M | 6.01% | $390.33M | 1.65 | $1.82B | 8.22 | ||
| OMER | OMEROS CORP | $10.26 | $15.78 | -34.98% | 7.89x | -26.94x | 74.35x | -11.72x | 0.40x | -$94.78M | -12.85% | -$63.33M | -0.88 | $1.05B | 11.63 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $53.32 | $41.50 | 28.49% | 38.09x | 13.42x | 3.17x | 1.66x | 0.54x | $767.06M | 7.47% | $6.21B | 32.27 | $8.66B | 17.96 | ||
| RPRX | ROYALTY PHARMA PLC | $54.01 | $40.53 | 33.25% | 28.28x | 10.13x | 9.67x | 3.13x | 0.61x | $2.34B | 9.92% | $9.94B | 22.75 | $39.47B | 33.93 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $10.88 | $16.53 | -34.17% | 5.31x | 23.15x | 5.20x | 3.13x | 0.67x | $56.42M | 8.88% | $205.80M | 3.52 | $548.72M | 3.79 | ||
| HALO | HALOZYME THERAPEUTICS INC | $66.28 | $71.66 | -7.51% | 22.39x | 8.00x | 5.19x | 35.79x | 0.41x | $667.65M | 8.53% | $219.64M | 1.86 | $9.69B | 15.54 | ||
| VCEL | VERICEL CORP | $34.45 | $9.29 | 271.01% | 80.12x | 71.46x | 5.99x | 4.94x | 1.68x | $47.49M | 2.71% | $356.23M | 7.02 | $1.74B | 43.16 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $232.76 | $97.25 | 139.34% | 29.46x | 25.83x | 16.86x | 4.68x | 1.45x | $122.22M | 2.64% | $997.32M | 50.16 | $5.00B | 22.18 | ||
| ASND | ASCENDIS PHARMA A | $216.60 | $85.14 | 154.41% | 22.96x | 17.44x | 13.21x | 23.43x | 2.14x | $52.94M | 0.39% | $574.09M | 9.24 | $13.83B | 148.35 | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $226.12 | $49.54 | 356.42% | 481.11x | 8.76x | 3.15x | 3.13x | 1.64x | $1.30B | 9.27% | $4.53B | 73.22 | $17.75B | 26.29 | ||
| SPRO | SPERO THERAPEUTICS INC | $2.83 | $5.83 | -51.45% | 10.48x | 4.14x | 2.65x | 3.10x | 0.22x | $7.24M | 4.45% | $52.93M | 0.92 | $110.21M | 7.11 | ||
| TECH | BIO-TECHNE CORP | $49.77 | $15.64 | 218.27% | 70.10x | 25.31x | 6.43x | 3.74x | 1.44x | $269.60M | 3.47% | $2.09B | 13.34 | $7.87B | 30.76 | ||
| TGTX | TG THERAPEUTICS INC | $36.64 | $18.92 | 93.62% | 11.38x | 24.41x | 7.56x | 9.62x | 7.44x | -$14.19M | -0.27% | $583.13M | 4.04 | $5.92B | 39.45 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $30.91 | $36.44 | -15.18% | 12.22x | 8.42x | 1.99x | 1.97x | 0.46x | $341.79M | 19.12% | $910.35M | 15.75 | $1.36B | 5.73 | ||
| UTHR | UNITED THERAPEUTICS CORP | $540.05 | $251.38 | 114.83% | 18.44x | 18.58x | 7.41x | 3.88x | 1.95x | $1.02B | 4.33% | $5.90B | 135.66 | $21.64B | 12.63 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $425.09 | $172.50 | 146.43% | 24.99x | 21.73x | 8.84x | 5.57x | 1.78x | $3.71B | 3.44% | $19.36B | 76.20 | $104.38B | 19.35 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $3.54 | $2.50 | 41.62% | 14.75x | 14.96x | 2.17x | 3.42x | 1.00x | $4.11M | 1.44% | $82.33M | 1.03 | $217.97M | 10.26 | ||
| EXEL | EXELIXIS INC | $48.54 | $31.35 | 54.85% | 15.56x | 14.74x | 5.28x | 6.30x | 1.13x | $917.69M | 7.32% | $1.94B | 7.49 | $12.14B | 11.50 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $31.27 | $15.14 | 106.53% | 17.28x | 16.26x | 6.40x | 3.78x | 1.96x | $208.13M | 5.44% | $1.01B | 8.28 | $3.07B | 9.18 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $1.99 | $1.77 | 12.44% | 10.47x | 9.16x | 2.08x | 2.38x | 0.90x | $13.00M | 8.19% | $67.23M | 0.84 | $127.11M | 5.69 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $602.92 | $450.09 | 33.95% | 14.17x | 12.75x | 4.20x | 2.01x | 0.93x | $4.11B | 6.56% | $31.42B | 302.15 | $62.95B | 10.96 | ||
| VCYT | VERACYTE INC | $47.80 | $12.54 | 281.19% | 43.06x | 42.47x | 7.02x | 2.84x | 2.47x | $155.34M | 4.09% | $1.34B | 16.90 | $3.59B | 31.19 | ||
| SRPT | SAREPTA THERAPEUTICS INC | $16.25 | $4.68 | 247.56% | 27.08x | 4.66x | 0.78x | 1.14x | 3.79x | $109.24M | 6.40% | $1.51B | 14.34 | $2.29B | 27.65 | ||
| INCY | INCYTE CORP | $92.24 | $67.22 | 37.22% | 12.65x | 11.71x | 3.43x | 3.28x | 1.12x | $1.45B | 7.89% | $5.62B | 28.21 | $15.00B | 8.02 | ||
| MDXG | MIMEDX GROUP INC | $3.57 | $1.59 | 124.95% | 17.00x | -50.00x | 1.36x | 2.19x | 2.64x | $69.36M | 13.08% | $242.94M | 1.64 | $389.56M | 7.15 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.